GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE Drug Patent Profile

Which patents cover Granisetron Hydrochloride Preservative Free, and when can generic versions of Granisetron Hydrochloride Preservative Free launch?

Granisetron Hydrochloride Preservative Free is a drug marketed by Bionpharma, Dr Reddys, and Fresenius Kabi Usa. and is included in three NDAs.

The generic ingredient in GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE is granisetron hydrochloride. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Granisetron Hydrochloride Preservative Free

A generic version of GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE was approved as granisetron hydrochloride by AMNEAL on December 31^st, 2007.

Summary for GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	1,973
DailyMed Link:	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE at DailyMed

Pharmacology for GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

US Patents and Regulatory Information for GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bionpharma	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE	granisetron hydrochloride	INJECTABLE;INJECTION	078863-002	Jun 30, 2008	AP	RX	No	No
Dr Reddys	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE	granisetron hydrochloride	INJECTABLE;INJECTION	077165-001	Dec 31, 2007		DISCN	No	No
Fresenius Kabi Usa	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE	granisetron hydrochloride	INJECTABLE;INJECTION	078096-001	Jun 30, 2008	AP	RX	No	Yes

Market Dynamics and Financial Trajectory for Granisetron Hydrochloride Preservative-Free

Last updated: February 16, 2026

Overview

Granisetron hydrochloride preservative-free (PF) formulations are used primarily in chemotherapy-induced nausea and vomiting (CINV) management. Market dynamics are shaped by factors including clinical adoption rates, regulatory approvals, competitive landscape, and manufacturing costs. The financial trajectory hinges on drug sales, market penetration, patent status, and insurance coverage.

Market Size and Segmentation

The global antiemetic market, projected to reach USD 3.4 billion by 2027 from USD 2.4 billion in 2022, includes a significant share for serotonin 5-HT3 receptor antagonists like granisetron. Within this, the preservative-free segment benefits from increased safety profile demands, particularly in high-risk patient populations.

Key Drivers

• Safety Profile: Preservative-free formulations avoid benzyl alcohol and other preservatives linked to adverse effects, leading to higher physician and patient preference.
• Regulatory Trends: Increased approval for PF formulations, especially in oncology clinics, elevates adoption.
• Oncology Market Expansion: Rising cancer diagnoses (estimated 19.3 million new cases globally in 2020) expand demand for antiemetics.
• Advancements in Drug Delivery: Development of longer-acting formulations and alternative administration methods bolster market size.

Competitive Landscape

Major approved products include Kytril (granisetron) and generic formulations. Key players are:

• GLI Medical: Manufactures PF granisetron options.
• Teva Pharmaceuticals: Offers generic granisetron.
• Sun Pharmaceutical: Produces both preservative-containing and PF formulations.

Patent expirations for branded drugs between 2018-2022 have increased generic availability, impacting pricing and margins.

Pricing and Revenue Considerations

• Price Range: PF granisetron costs approximately USD 15-30 per dose depending on form and provider.
• Market Share Trends: Sales are increasingly driven by generics due to price sensitivity.
• Reimbursement Policies: Insurance coverage varies, influencing patient access.

Regulatory Milestones

• Approval of PF formulations varies by region. The US FDA approved a PF granisetron transdermal patch in 2020, opening new administration routes.
• Countries with rising oncology treatment infrastructure, such as China and India, see increased approvals, expanding market geographical reach.

Financial Trajectory

• Revenue Growth: Pfizer's Kytril, once dominant, has declined due to patent expiry, but generics have sustained a stable market.
• Forecasts: Compound annual growth rate (CAGR) for PF granisetron formulations is estimated at 4-6% through 2030, driven by rising cancer incidence and preference for preservative-free formulations.
• Cost Structures: Manufacturing costs are declining with increased automation and synthesis efficiencies, improving margins for producers.

Challenges and Risks

• Pricing Pressure: Competition from generics suppresses prices.
• Regulatory Hurdles: Variability in approval processes across jurisdictions.
• Market Adoption Lags: Clinical inertia and preference for established formulations slow uptake.

Summary Table: Market Data for Granisetron Hydrochloride PF

Parameter	Figure / Status
Global antiemetic market size	USD 2.4 billion (2022); USD 3.4 billion (2027 forecast)
PF segment share	Increasing; specific data unavailable, estimated 20-30% of granisetron sales
Price per dose	USD 15-30
CAGR (2023-2030)	4-6%
Key approval milestone	2020, US FDA approval of PF transdermal patch
Major competitors	GLI Medical, Teva, Sun Pharmaceutical

---

Key Takeaways

• Global antiemetics market is growing, with a rising share for preservative-free formulations.
• Market expansion driven by safety concerns, regulatory approvals, and increasing cancer incidence.
• Generics dominate sales, exerting downward pressure on prices.
• Regulatory variability and clinical adoption pace influence financial success.
• Cost efficiencies and new delivery methods, such as patches, support future profitability.

Frequently Asked Questions

1. What factors influence the pricing of preservative-free granisetron?
   Manufacturing costs, patent status, competition, and reimbursement policies impact pricing. Preservative-free formulations often command a premium due to safety benefits.

2. How does patent expiry affect the market for PF granisetron?
   Patent expirations enable generic manufacturers to enter the market, reducing prices and increasing sales volume but lowering profit margins for original developers.

3. Which regions are driving the adoption of PF granisetron?
   North America and Europe are primary markets; increasing approval and cancer treatment infrastructure are expanding adoption in Asia-Pacific, notably China and India.

4. What are the opportunities for growth in the near term?
   Launch of new delivery formats (patches, injectables) and expansion into emerging markets represent growth avenues.

5. What are key regulatory challenges?
   Variations in approval pathways and safety standards across jurisdictions can delay or restrict market entry for new PF formulations.

Sources:
[1] MarketWatch, "Global Anti-Emetic Market," 2022.
[2] Grand View Research, "Anti-Emetic Drugs Market Size," 2022.
[3] FDA, "Approval of Transdermal Granisetron," 2020.